Y-mAbs Therapeutics Future Growth

How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

32.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:YMAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	93	-39	N/A	N/A	4
12/31/2024	86	-53	-99	-99	6
12/31/2023	64	-70	-103	-99	9
9/30/2022	43	-134	-102	-101	N/A
6/30/2022	40	-135	-100	-100	N/A
3/31/2022	40	-117	-96	-96	N/A
12/31/2021	35	-55	-104	-103	N/A
9/30/2021	46	-38	-87	-86	N/A
6/30/2021	37	-42	-93	-92	N/A
3/31/2021	26	-60	-102	-101	N/A
12/31/2020	21	-119	-91	-91	N/A
9/30/2020	N/A	-123	-99	-98	N/A
6/30/2020	N/A	-114	-97	-95	N/A
3/31/2020	N/A	-91	-84	-82	N/A
12/31/2019	N/A	-81	-75	-73	N/A
9/30/2019	N/A	-72	-63	-62	N/A
6/30/2019	N/A	-59	-51	-50	N/A
3/31/2019	N/A	-52	-48	-48	N/A
12/31/2018	N/A	-43	-41	-41	N/A
9/30/2018	N/A	-38	-34	-34	N/A
6/30/2018	N/A	-31	-28	-27	N/A
3/31/2018	N/A	-24	-19	-19	N/A
12/31/2017	N/A	-19	-16	-16	N/A

Earnings vs Savings Rate: YMAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: YMAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: YMAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: YMAB's revenue (21.7% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: YMAB's revenue (21.7% per year) is forecast to grow faster than 20% per year.